Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

MRK 57.60 +0.09 (0.16%)
price chart
Merck & Co., Inc. Seeks FDA Approval As Keytruda Is Shown To Shrink Lung ...
Merck & Co., Inc. (NYSE:MRK) announced that it has submitted an application to the US Food and Drug Administration (FDA) seeking approval for its cancer drug Keytruda, to treat patients with non-small cell lung cancer (NSCLC), after a study comparing ...
Merck & Co. Seek FDA Approval for Melanoma Drug Keytruda  Healthcare Global
Test May Show Merck Melanoma Drug's Success in Lung Cancer  Bloomberg
Merck & Co., Inc. Announces $434 Million Collaboration With Arvinas Over ...
Merck & Co., Inc. (NYSE:MRK) announced Tuesday its decision to join hands with a privately held biotech firm Arvinas LLC for expediting the development of novel therapeutics, taking advantage of Arvinas' proteolysis-targeting chimera (PROTAC ...
Merck & Co. Inc. (NYSE:MRK) Releases A Strategic Alliances In Which ...  StreetWise Report
Merck & Co., Inc. (NYSE:MRK) Ties Up With ArvinasFor A $434 Million ...  USMarketsDaily (blog)
Merck & Co. Inc. (MRK) Closes 0.05% Up on the Day for April 22
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move 0.05% to $57.69, representing a per-share move of $0.03, on volume of 7.89 million shares for Wednesday.
Merck & Co. Inc. (MRK) Closes 1.28% Up on the Day for April 20
Merck & Co. Inc. currently has a total float of 2.83 billion shares and moves 12.18 million a day, on average. The stock opened at $57.50 on April 20 and traded between a low of $57.39 and a high of $58.00.
Morgan Stanley Awaits This Merck Data
In a report published Tuesday, Morgan Stanley analysts maintained an Equal-Weight rating on Merck & Co. (NYSE: MRK), saying that the company is filing in select patients in lung cancer earlier than expected, but its best to wait for survival data ...
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on April 16
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.04%. The DJIA closed at 18,105.80, which is a -0.04% change from the previous day's close.
Merck & Co. Inc. (MRK) Closes 1.04% Down on the Day for April 16
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -1.04% to $57.84, representing a per-share move of $0.61, on volume of 6.36 million shares for Thursday.
Company Update: Merck & Co Inc (NYSE:MRK) - Merck Reaffirms Continued ...
Merck & Co Inc (NYSE:MRK) [Business Wire] - Merck , known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, ...
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for ...  MarketWatch
Stock to Follow: Merck & Co. Inc. (NYSE:MRK)
[Business Wire] Merck & Co., Inc. (NYSE:MRK)(TREND ANALYSIS) known as MSD outside of the United States and Canada, today announced a collaboration with the American Diabetes Association (ADA).
Market Update: Merck & Co Inc (NYSE:MRK) - Merck to Hold First-Quarter ...  Jutia Group
Merck & Co. Receives "Hold" Rating from Zacks (MRK)  WKRB News
Breakthrough Designation For Merck & Co., Inc. (NYSE:MRK) Hepatitis C ...
Merck & Co., Inc. (NYSE:MRK) executives appear to have won a reprieve of sorts on Wednesday, when the U.S. regulatory body, the FDA, announced 'Breakthrough Designation' for its Hepatitis C drug.
Mercks HCV Combo Drug Gets Two Breakthrough Status  Zacks.com
Merck Gets Breakthrough Designation for Hepatitis C Drugs  Wall Street Journal